Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from InflaRx ( (IFRX) ) is now available.
InflaRx N.V., a Nasdaq-listed biopharmaceutical group based in Germany and the U.S., focuses on anti-inflammatory drugs that inhibit the complement activation factor C5a and its receptor, C5aR. Its lead candidate is izicopan, an oral C5a receptor inhibitor in early- to mid-stage trials for several inflammatory diseases, complemented by vilobelimab, an intravenous anti-C5a antibody with clinical data supporting disease-modifying potential.
On April 28, 2026, InflaRx reported that Nasdaq confirmed the company had regained compliance with the exchange’s $1.00 minimum bid price requirement after its shares traded at or above that level for 10 consecutive business days from April 13 to April 24, 2026. The resolution of the deficiency notice, originally issued on March 11, 2026, removes the immediate threat to InflaRx’s Nasdaq listing and stabilizes its market standing, a key consideration for investors and ongoing access to capital markets.
The most recent analyst rating on (IFRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, continued losses, and cash burn despite low debt). Technicals are a partial offset with strong momentum and price above key averages, though signals are overbought. Valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V., listed on Nasdaq as IFRX, is a biopharmaceutical company developing anti-inflammatory therapeutics that target the complement system, specifically the C5a activation factor and its receptor C5aR. Its pipeline includes the oral C5a receptor inhibitor izicopan for inflammatory diseases such as hidradenitis suppurativa and the intravenous anti-C5a antibody vilobelimab, supported by operations in Germany and the U.S.
Founded in 2007, InflaRx applies proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly specific complement inhibitors. The company has reported promising Phase 1 and Phase 2a data for izicopan and has demonstrated disease-modifying activity for vilobelimab across multiple clinical studies, underscoring its focus on complement-driven inflammatory conditions.
Average Trading Volume: 596,355
Technical Sentiment Signal: Buy
Current Market Cap: $107M
For a thorough assessment of IFRX stock, go to TipRanks’ Stock Analysis page.